You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

You’ve been redirected to the new Cancer Care Ontario website. You can also visit the archived website, which is no longer being maintained.

Guidelines & Advice
About Guidelines Email Guidelines Team

Bone Health and Bone-Targeted Therapies for Prostate Cancer

Version: 2 ID: 3-14 Sep 2016
Type of Content: Guidelines & Advice
Document Status: Current
Authors:
S. Alibhai, K. Zukotynski, C. Walker-Dilks, U. Emmenegger, A. Finelli, S. Morgan, S. Hotte, E. Winquist

Guideline Objective

To evaluate the effectiveness of therapies targeting bone across all stages of prostate cancer

Patient Population

Men with prostate cancer

Intended Guideline Users

Healthcare professionals, health care administrators, medical or radiation oncologists who treat genitourinary cancer, urologists, radiologists, nuclear medicine physicians, geriatricians, primary care physicians, and osteoporosis experts.

Research Question(s)

  1. Can therapeutic interventions reduce osteoporosis-related outcomes in men with prostate cancer receiving androgen deprivation therapy (ADT)?
  2. Can therapeutic interventions prevent bone metastases in men with prostate cancer?
  3. Can bone-targeted therapies reduce the incidence of SREs, reduce pain, or improve quality of life in men with prostate cancer metastatic to bone?
  4. Can bone-targeted therapies improve overall survival in men with established prostate cancer and bone metastases?
pdf download Summary (PDF) (194.27 KB)
pdf download Full Report (PDF) (1.82 MB)